Vcjd Sensory Symptoms Case Study

On By In 1

1. Prusiner SB. Cell biology. A unifying role for prions in neurodegenerative diseases.Science. 2012;336:1511–3. 10.1126/science.1222951 [PMC free article][PubMed][Cross Ref]

2. Barria MA, Ironside JW, Head MW. Exploring the zoonotic potential of animal prion diseases: in vivo and in vitro approaches.Prion. 2014;8:85–91. 10.4161/pri.28124 [PubMed][Cross Ref]

3. Diack AB, Head MW, McCutcheon S, Boyle A, Knight R, Ironside JW, et al. Variant CJD: 18 years of research and surveillance.Prion. 2014;8:286–95. 10.4161/pri.29237 [PMC free article][PubMed][Cross Ref]

4. Sanchez-Juan P, Cousens SN, Will RG, van Duijn CM. Source of variant Creutzfeldt-Jakob disease outside United Kingdom.Emerg Infect Dis. 2007;13:1166–9. 10.3201/eid1308.070178 [PMC free article][PubMed][Cross Ref]

5. Food and Drug Administration. 2011. Meeting materials, Transmissible Spongiform Encephalopthies Advisory Committee [cited 2014 Oct 1].

6. Moda F, Gambetti P, Notari S, Concha-Marambio L, Catania M, Park K-W, et al. Prions in the urine of patients with variant Creutzfeldt-Jakob disease.N Engl J Med. 2014;371:530–9. 10.1056/NEJMoa1404401 [PMC free article][PubMed][Cross Ref]

7. Heath CA, Cooper SA, Murray K, Lowman A, Henry C, MacLeod MA, et al. Diagnosing variant Creutzfeldt-Jakob disease: a retrospective analysis of the first 150 cases in the UK.J Neurol Neurosurg Psychiatry. 2011;82:646–51. 10.1136/jnnp.2010.232264 [PubMed][Cross Ref]

8. Will RG, Ironside JW, Zeidler M, Cousens SN, Estibeiro K, Alperovitch A, et al. A new variant of Creutzfeldt-Jakob disease in the UK.Lancet. 1996;347:921–5. 10.1016/S0140-6736(96)91412-9 [PubMed][Cross Ref]

9. Barash J. Identification of Creutzfeldt-Jakob disease variants. [author reply 1045–6]. Arch Neurol. 2009;66:1045. 10.1001/archneurol.2009.143 [PubMed][Cross Ref]

10. Appleby BS, Appleby KK, Crain BJ, Onyike CU, Wallin MT, Rabins PV. Characteristics of established and proposed sporadic Creutzfeldt-Jakob disease variants.Arch Neurol. 2009;66:208–15 . [PubMed]

11. Heath CA, Cooper SA, Murray K, Lowman A, Henry C, MacLeod MA, et al. Validation of diagnostic criteria for variant Creutzfeldt-Jakob disease.Ann Neurol. 2010;67:761–70 . [PubMed]

12. World Health Organization Department of Communicable Disease Surveillance and Response. WHO recommended surveillance standards, 1999. [cited 2015 Mar 8].

13. Zerr I, Kallenberg K, Summers DM, Romero C, Taratuto A, Heinemann U, et al. Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease.Brain. 2009;132:2659–68 . 10.1093/brain/awp191 [PMC free article][PubMed][Cross Ref]

14. Collie DA, Summers DM, Sellar RJ, Ironside JW, Cooper S, Zeidler M, et al. Diagnosing variant Creutzfeldt-Jakob disease with the pulvinar sign: MR imaging findings in 86 neuropathologically confirmed cases.AJNR Am J Neuroradiol. 2003;24:1560–9 . [PubMed]

15. Ugnon-Café S, Dorey A, Bilheude JM, Streichenberger N, Viennet G, Meyronet D, et al. Rapid screening and confirmatory methods for biochemical diagnosis of human prion disease.J Virol Methods. 2011;175:216–23. 10.1016/j.jviromet.2011.05.016 [PubMed][Cross Ref]

16. Hill AF, Butterworth RJ, Joiner S, Jackson G, Rossor MN, Thomas DJ, et al. Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy samples.Lancet. 1999;353:183–9. 10.1016/S0140-6736(98)12075-5 [PubMed][Cross Ref]

17. Lukic A, Mead S, Rudge P, Collinge J. Comment on validation of diagnostic criteria for variant Creutzfeldt-Jakob disease. [author reply 212–3]. Ann Neurol. 2011;69:212. 10.1002/ana.22273 [PubMed][Cross Ref]

18. Green AJ, Thompson EJ, Stewart GE, Zeidler M, McKenzie JM, MacLeod MA, et al. Use of 14-3-3 and other brain-specific proteins in CSF in the diagnosis of variant Creutzfeldt-Jakob disease.J Neurol Neurosurg Psychiatry. 2001;70:744–8. 10.1136/jnnp.70.6.744 [PMC free article][PubMed][Cross Ref]

19. Zeidler M, Stewart GE, Barraclough CR, Bateman DE, Bates D, Burn DJ, et al. New variant Creutzfeldt-Jakob disease: neurological features and diagnostic tests.Lancet. 1997;350:903–7. 10.1016/S0140-6736(97)07472-2 [PubMed][Cross Ref]

20. Beck JA, Poulter M, Campbell TA, Adamson G, Uphill JB, Guerreiro R, et al. PRNP allelic series from 19 years of prion protein gene sequencing at the MRC Prion Unit.Hum Mutat. 2010;31:E1551–63. 10.1002/humu.21281 [PubMed][Cross Ref]

21. Jackson GS, Burk-Rafel J, Edgeworth JA, Sicilia A, Abdilahi S, Korteweg J, et al. Population screening for variant Creutzfeldt-Jakob disease using a novel blood test: diagnostic accuracy and feasibility study.JAMA Neurol. 2014;71:421–8. 10.1001/jamaneurol.2013.6001 [PMC free article][PubMed][Cross Ref]

22. Edgeworth JA, Farmer M, Sicilia A, Tavares P, Beck J, Campbell T, et al. Detection of prion infection in variant Creutzfeldt-Jakob disease: a blood-based assay.Lancet. 2011;377:487–93. 10.1016/S0140-6736(10)62308-2 [PubMed][Cross Ref]

23. Parchi P, Giese A, Capellari S, Brown P, Schulz-Schaeffer W, Windl O, et al. Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects.Ann Neurol. 1999;46:224–33. 10.1002/1531-8249(199908)46:2<224::AID-ANA12>3.0.CO;2-W [PubMed][Cross Ref]

24. Gambetti P, Kong Q, Zou W, Parchi P, Chen SG. Sporadic and familial CJD: classification and characterisation.Br Med Bull. 2003;66:213–39. 10.1093/bmb/66.1.213 [PubMed][Cross Ref]

25. Gambetti P, Cali I, Notari S, Kong Q, Zou W-Q, Surewicz WK. Molecular biology and pathology of prion strains in sporadic human prion diseases.Acta Neuropathol. 2011;121:79–90. 10.1007/s00401-010-0761-3 [PMC free article][PubMed][Cross Ref]

26. Sikorska B, Knight R, Ironside JW, Liberski PP. Creutzfeldt-Jakob disease.Adv Exp Med Biol. 2012;724:76–90. 10.1007/978-1-4614-0653-2_6 [PubMed][Cross Ref]

27. Mihara M, Sugase S, Konaka K, Sugai F, Sato T, Yamamoto Y, et al. The “pulvinar sign” in a case of paraneoplastic limbic encephalitis associated with non-Hodgkin’s lymphoma.J Neurol Neurosurg Psychiatry. 2005;76:882–4. 10.1136/jnnp.2004.049783 [PMC free article][PubMed][Cross Ref]

28. Ryan AM, Ryan J, Wan-Ahmed M, Hardiman O, Farrell MA, McNamara B, et al. Vacuolar leucoencephalopathy and pulvinar sign in association with coeliac disease. BMJ Case Rep. 2009;2009:pii: bcr08.2008.0650. PMID: 20414170[PMC free article][PubMed]

29. Schmidt C, Plickert S, Summers D, Zerr I. Pulvinar sign in Wernicke’s encephalopathy.CNS Spectr. 2010;15:215–8 . [PubMed]

30. US Census Bureau. The foreign-born population in the United States [cited 2014 Aug 27].

31. Garske T, Ghani AC. Uncertainty in the tail of the variant Creutzfeldt-Jakob disease epidemic in the UK.PLoS ONE. 2010;5:e15626. 10.1371/journal.pone.0015626 [PMC free article][PubMed][Cross Ref]

32. Ghani AC, Donnelly CA, Ferguson NM, Anderson RM. Updated projections of future vCJD deaths in the UK.BMC Infect Dis. 2003;3:4. 10.1186/1471-2334-3-4 [PMC free article][PubMed][Cross Ref]

33. Valleron AJ, Boelle PY, Will R, Cesbron JY. Estimation of epidemic size and incubation time based on age characteristics of vCJD in the United Kingdom.Science. 2001;294:1726–8. 10.1126/science.1066838 [PubMed][Cross Ref]

34. Brown P, Brandel J-P, Sato T, Nakamura Y, MacKenzie J, Will RG, et al. Iatrogenic Creutzfeldt-Jakob disease, final assessment.Emerg Infect Dis. 2012;18:901–7. 10.3201/eid1806.120116 [PMC free article][PubMed][Cross Ref]

35. Collinge J, Whitfield J, McKintosh E, Beck J, Mead S, Thomas DJ, et al. Kuru in the 21st century—an acquired human prion disease with very long incubation periods.Lancet. 2006;367:2068–74. 10.1016/S0140-6736(06)68930-7 [PubMed][Cross Ref]

36. Boëlle P-Y, Cesbron J-Y, Valleron A-J. Epidemiological evidence of higher susceptibility to vCJD in the young.BMC Infect Dis. 2004;4:26 . 10.1186/1471-2334-4-26 [PMC free article][PubMed][Cross Ref]

37. Gill ON, Spencer Y, Richard-Loendt A, Kelly C, Dabaghian R, Boyes L, et al. Prevalent abnormal prion protein in human appendixes after bovine spongiform encephalopathy epizootic: large scale survey.BMJ. 2013;347:f5675. 10.1136/bmj.f5675 [PMC free article][PubMed][Cross Ref]

Similarly the trend of BSE cases shows a peak of reported cases in 1992 in UK, followed by a lower peak in 2002 in the other EU countries (EU non-UK) [11]. The time period between peaks of BSE and vCJD cases in the UK is around eight years; while the time period between peaks of BSE and vCJD cases in EU non-UK countries is only two years.

In theEU vCJD has tended to affect younger individuals with median age of onset at 28 year (range 11-74). Sporadic CJD usually affects middle-aged and elderly individuals.
The median duration of illness in the EU is 14 month (range 6-114).

Clinical features and diagnosis

Incubation period: The estimated mean incubation period (defined as the time from infection to death) for infection via primary transmission is estimated to be approximately the delay from the peak of exposure to BSE which occurred in 1989/1990 to the peak in the vCJD deaths which occurred in 2000 [12-14]..The incubation period in transfusion transmitted vCJD has been between 6.5 and 8 years.

In a recent study of French vCJD cases, the incubation period has been estimated to be around 13 years (95% CI: 9,7-17,9 years) [15].  The incubation period is not dependant on age [16], however age-dependent susceptibility/exposure is estimated to be highest in teenagers and young adults in line with previous estimates [13]. 

Clinical presentation: Clinical descriptions of all forms of CJD have been developed by the National Creutzfeldt-Jakob Disease Surveillance Unit in the UK: patients with vCJD have prominent early psychiatric (depression, anxiety and withdrawal) or sensory symptoms with a delayed onset of neurological abnormalities. Ataxia develops at around 6 months, and dementia and myoclonus are seen later in the illness. The disease always progresses to death [17,18].

Diagnosis: Clinical and investigative features, which are included in the diagnosis criteria, may be indicative of the diagnosis of vCJD but are never definitive as case confirmation requires neuropathological examination (link to case definition). Important diagnostic tools include:

  • EEG shows a typical periodic pattern in many cases of sporadic CJD, but this is rarely seen in vCJD. 
  • MRI brain scan shows pulvinar high signal in 90% of cases of vCJD and basal ganglia high signal in about 70% of cases of sporadic CJD.
  • CSF14-3-3 protein is elevated in 90% of cases of sporadic CJD and 50% of vCJD cases.

Neuropathological examination, usually after autopsy, is necessary for diagnostic confirmation and is also the definitive method for distinguishing between sporadic and variant CJD.

Treatment: Only palliative treatment is possible. No curative treatment is available.

Preventive measures
Since 1989, several control and prevention measures have been implemented in the EU [19]. The feed ban is the basic preventive measure laid down against TSE and consists of a ban on the use of processed animal protein (PAP) in feed for farmed animals. Based on scientific findings that linked the spread of BSE to the consumption of contaminated PAP feed, a ban on the feeding of mammalian processed animal protein to cattle, sheep and goats was introduced in the UK in 1988 and in other member states in July 1994. Aiming at eradication of certain TSE, the ban was expanded in January 2001 with the feeding of all processed animal proteins to all farmed animals being prohibited, with certain limited exceptions (TSE regulation). In 2009 a further ban on the use of milk and milk products coming from classical scrapie infected flocks for feeding ruminants was set out [20,21]. As a result, the number of BSE affected cattle in the UK has declined steadily, with only 3 reported cases so far in 2013 (figure 3) [11]. The probability of food-borne exposure to prion diseases in the EU appears now to be very limited.

To date, there has been no known association between primary vCJD and occupation, medicines, immunising agents, gelatin, or surgery (including the use of catgut sutures). Nevertheless, vCJD infection has been observed in three recipients of blood transfusions from two donors who later developed the disease and one blood recipient who died of another cause without clinical symptoms, but who at autopsy had prions in spleen and lymph nodes [5-8,22] . The possibility of a risk has been assessed for plasma products, human organ and tissue transplants and contaminated surgical instruments or devices, but, to date, no definite transmission through these routes has been identified. However, prions are remarkably stable and relatively resistant to proteases, high temperatures and UV-radiation, as well as to commonly used disinfectants [4].  

Key areas of uncertainty

The vCJD epidemic peaked in the EU in the period 1999-2004. The incidence has decreased steadily after the implementation of stringent prevention measures and the epidemic is now in its tail [12]. There are, however, remaining concerns and uncertainties:

  • Genetic susceptibility: Up to now, all tested cases of vCJD have been methionine homozygotes at codon 129 of the PrP gene (a genotype present in approximately 40% of Caucasian populations). Recently, a possible vCJD case was reported in a 30-year old man who was heterozygous at codon 129 [23]. However, the case was not confirmed. If other genotypes are not completely resistant to infection but have longer incubation periods, as suggested in kuru and growth hormone-related CJD, subsequent epidemics in these genotypes may yet appear [12].
  • Sub-clinical forms: Persons with latent disease undergoing surgical procedures could result in instrument contamination with a risk of secondary transmission [10,24] . The first evidence of transmission through blood transfusion raised concerns about iatrogenic transmission and there is the possibility of pre-clinical or sub-clinical prion-associated infection in an unknown proportion of the population [4].
  • Under-ascertainment of cases: While ascertainment of cases is probably good for young adults, it is still possible that cases of vCJD in old people are missed, because of the small proportion of those dying from dementia who undergo post mortem neuropathological examination [10].
  • Clinical features: It is possible that infection with BSE prions could produce symptoms different than those described until now for vCJD, for example in persons with genotypes other than MM at codon 129 of the prion protein gene [10,24].

During recent years, evidence has been accumulating that protein misfolding is central in the causation of a range of neurodegenerative disorders, including Alzheimer’s disease and Parkinson’s disease.

  • Partial lift of feed bans: In 2008 and 2009 the TSE regulation was amended to provide for a derogation from the general prohibition of feeding animal protein to ruminants with a view to allowing the feeding of proteins derived from fish to young animals of ruminant species, subject to certain conditions [20]. This change in policy may increase the risk of TSE transmission to cattle. Due to the long latency of the vCJD the effects of any potential human exposure to contaminated animal product will be evident in the years to come.
  • Atypical BSE: As part of the massive testing for BSE at slaughterhouses in the EU, abnormal prion positive cows without symptoms have been detected in Europe and North America. These prion strains were initially detected in Italy and referred as to bovine amyloidotic spongiform encephalopathy (BASE). Animal tests in mice have shown an evolution of BASE strain towards BSE strain and it has been suggested that the BASE strain is the origin of the BSE strain that has caused the epidemics in humans and animals [25] . A recent study suggests a potential link between BASE and a subset of sporadic CJD cases based on the biochemical similarity of the strains [26] .

EU Surveillance for variant CJD

The surveillance of vCJD became mandatory in the EU in 2000 (Commission Decision 2000/96/EC). The EuroCJD network, established in 1993, was evaluated and transferred under the responsibility of ECDC in 2007.

The surveillance is currently performed by the EuroCJD network, co-ordinated from the National CJD Research & Surveillance Unit based in Edinburgh and funded by ECDC. There are now 29 collaborating centres from EU Member States and EEA/EFTA countries. The case definitions for vCJD apply to all EU countries (link).
The reporting, including all historical cases was established in TESSy in 2012.


1.         Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science. 1982 04/09;216(4542):136-44.
2.         Castilla J, Gonzalez-Romero D, Saa P, Morales R, De Castro J, Soto C. Crossing the species barrier by prp(sc) replication in vitro generates unique infectious prions. Cell. 2008 Sep 5;134(5):757-68. PubMed PMID: 18775309. Pubmed Central PMCID: PMC2740631. Epub 2008/09/09. eng.
3.         Bruce ME, Will RG, Ironside JW, McConnell I, Drummond D, Suttie A, et al. Transmissions to mice indicate that 'new variant' cjd is caused by the bse agent. Nature. 1997 10/02;389(6650):498-501.
4.         Collee JG, Bradley R, Liberski PP. Variant cjd (vcjd) and bovine spongiform encephalopathy (bse): 10 and 20 years on: Part 2. Folia neuropathologica / Association of Polish Neuropathologists and Medical Research Centre, Polish Academy of Sciences. 2006;44(2):102-10. PubMed PMID: 16823692. Epub 2006/07/11. eng.
5.         Llewelyn CA, Hewitt PE, Knight RSG, Amar K, Cousens S, Mackenzie J, et al. Possible transmission of variant creutzfeldt-jakob disease by blood transfusion. Lancet. 2004 02/07;363(9407):417-21.
6.         Peden AH, Head MW, Ritchie DL, Bell JE, Ironside JW. Preclinical vcjd after blood transfusion in a prnp codon 129 heterozygous patient. Lancet. 2004 08/07;364(9433):527-9.
7.         Chohan G, Llewelyn C, Mackenzie J, Cousens S, Kennedy A, Will R, et al. Variant creutzfeldt-jakob disease in a transfusion recipient: Coincidence or cause? Transfusion. 2010 05/;50(5):1003-6.
8.         Hewitt PE, Llewelyn CA, Mackenzie J, Will RG. Creutzfeldt-jakob disease and blood transfusion: Results of the uk transfusion medicine epidemiological review study. Vox Sang. 2006 Oct;91(3):221-30. PubMed PMID: 16958834. Epub 2006/09/09. eng.
9.         Heymann DLAPHA. Control of communicable diseases manual. Washington, DC: American Public Health Association; 2004.
10.       Smith PG, Cousens SN, d' Huillard Aignaux JN, Ward HJ, Will RG. The epidemiology of variant creutzfeldt-jakob disease. Curr Top Microbiol Immunol. 2004;284:161-91. PubMed PMID: 15148992. Epub 2004/05/20. eng.
11.       Annual reports of member states on bse and scrapie 2013.
12.       Garske T, Ghani AC. Uncertainty in the tail of the variant creutzfeldt-jakob disease epidemic in the uk. PloS one. 2010;5(12):e15626. PubMed PMID: 21203419. Pubmed Central PMCID: PMC3009744. Epub 2011/01/05. eng.
13.       Ghani AC, Ferguson NM, Donnelly CA, Anderson RM. Short-term projections for variant creutzfeldt-jakob disease onsets. Statistical methods in medical research. 2003 Jun;12(3):191-201. PubMed PMID: 12828241. Epub 2003/06/28. eng.
14.       Valleron AJ, Boelle PY, Will R, Cesbron JY. Estimation of epidemic size and incubation time based on age characteristics of vcjd in the united kingdom. Science. 2001 Nov 23;294(5547):1726-8. PubMed PMID: 11721058. Epub 2001/11/27. eng.
15.       Chadeau-Hyam M, Clarke PS, Guihenneu-Jouyaux C, Cousens SN, Will RG, Ghani AC. An application of hidden markov models to the french variant creutzfeldt-jakob disease epidemic. Appl Statist. 2010 Jan 2010;59(Part 5):15. eng.
16.       Ghani AC, Ferguson NM, Donnelly CA, Anderson RM. Predicted vcjd mortality in great britain. Nature. 2000 Aug 10;406(6796):583-4. PubMed PMID: 10949288. Epub 2000/08/19. eng.
17.       Ironside JW. Variant creutzfeldt-jakob disease: Risk of transmission by blood transfusion and blood therapies. Haemophilia : the official journal of the World Federation of Hemophilia. 2006 Mar;12 Suppl 1:8-15; discussion 26-8. PubMed PMID: 16445812. Epub 2006/02/01. eng.
18.       Turner MLAAoBB. Creutzfeldt-jakob disease : Managing the risk of transmission by blood, plasma, and tissues. Bethesda, Md.: AABB Press; 2006.
19.       Bradley R, Collee JG, Liberski PP. Variant cjd (vcjd) and bovine spongiform encephalopathy (bse): 10 and 20 years on: Part 1. Folia neuropathologica / Association of Polish Neuropathologists and Medical Research Centre, Polish Academy of Sciences. 2006;44(2):93-101. PubMed PMID: 16823691. Epub 2006/07/11. eng.
20.      Chronological legislation eu about bse 2013.
21.       Commission decision 2000/418/ec regulating the use of material presenting risks as regards transmissible spongiform encephalopathies, 2000/418/EC OJ(2000).
22.      Soldan K. Uk blood donors identified as at increased risk of vcjd are to be notified of their status 2005 [updated 07/; cited 10 7].
23.       Kaski D Fau - Mead S, Mead S Fau - Hyare H, Hyare H Fau - Cooper S, Cooper S Fau - Jampana R, Jampana R Fau - Overell J, Overell J Fau - Knight R, et al. Variant cjd in an individual heterozygous for prnp codon 129. (1474-547X (Electronic)).
24.       Hilton DA. Pathogenesis and prevalence of variant creutzfeldt-jakob disease. The Journal of pathology. 2006 Jan;208(2):134-41. PubMed PMID: 16362983. Epub 2005/12/20. eng.
25.       Capobianco R, Casalone C, Suardi S, Mangieri M, Miccolo C, Limido L, et al. Conversion of the base prion strain into the bse strain: The origin of bse? PLoS pathogens. 2007 Mar;3(3):e31. PubMed PMID: 17352534. Pubmed Central PMCID: PMC1817656. Epub 2007/03/14. eng.
26.       Comoy EE, Casalone C, Lescoutra-Etchegaray N, Zanusso G, Freire S, Marce D, et al. Atypical bse (base) transmitted from asymptomatic aging cattle to a primate. PloS one. 2008;3(8):e3017. PubMed PMID: 18714385. Pubmed Central PMCID: PMC2515088. Epub 2008/08/21. eng.


Leave a Reply

Your email address will not be published. Required fields are marked *